Daxor Corp
NASDAQ:DXR
Daxor Corp
NASDAQ:DXR
Price:
8.047
USD
3.17%
Market Closed
Market Cap:
39.7m
USD
Daxor Corp
Total Other Income
|
Daxor Corp
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daxor Corp
NASDAQ:DXR
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Other Income
-$39m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Other Income
-$16m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Other Income
$60m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Other Income
$558m
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Other Income
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Daxor Corp
Glance View
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The firm intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The firm seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.
DXR
Intrinsic Value
3.416
USD
Overvaluation 58%
You don't have any saved screeners yet